DK0811062T3 - Frembringelse af humane cytotoksiske T-celler, der er specifikke for selvassocierede antigener af carcinomer, og anvendelser heraf - Google Patents

Frembringelse af humane cytotoksiske T-celler, der er specifikke for selvassocierede antigener af carcinomer, og anvendelser heraf

Info

Publication number
DK0811062T3
DK0811062T3 DK96907061T DK96907061T DK0811062T3 DK 0811062 T3 DK0811062 T3 DK 0811062T3 DK 96907061 T DK96907061 T DK 96907061T DK 96907061 T DK96907061 T DK 96907061T DK 0811062 T3 DK0811062 T3 DK 0811062T3
Authority
DK
Denmark
Prior art keywords
carcinomas
self
applications
production
associated antigens
Prior art date
Application number
DK96907061T
Other languages
English (en)
Inventor
Jeffrey Schlom
Dennis Panicali
Kwong Y Tsang
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK0811062T3 publication Critical patent/DK0811062T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK96907061T 1995-02-22 1996-02-13 Frembringelse af humane cytotoksiske T-celler, der er specifikke for selvassocierede antigener af carcinomer, og anvendelser heraf DK0811062T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/396,385 US6001349A (en) 1995-02-22 1995-02-22 Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
PCT/US1996/002156 WO1996026271A1 (en) 1995-02-22 1996-02-13 Generation of human cytotoxic t-cells specific for carcinoma self-associated antigens and uses thereof

Publications (1)

Publication Number Publication Date
DK0811062T3 true DK0811062T3 (da) 2009-10-26

Family

ID=23566990

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96907061T DK0811062T3 (da) 1995-02-22 1996-02-13 Frembringelse af humane cytotoksiske T-celler, der er specifikke for selvassocierede antigener af carcinomer, og anvendelser heraf

Country Status (10)

Country Link
US (2) US6001349A (da)
EP (1) EP0811062B1 (da)
JP (1) JP4059920B2 (da)
AU (1) AU711899B2 (da)
CA (1) CA2213451C (da)
DE (1) DE69637969D1 (da)
DK (1) DK0811062T3 (da)
ES (1) ES2329427T3 (da)
PT (1) PT811062E (da)
WO (1) WO1996026271A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6946133B1 (en) * 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
US20010036928A1 (en) * 1996-04-22 2001-11-01 Chamberlain Ronald S. Heterologous boosting immunizations
EP2112225A1 (en) * 1996-07-25 2009-10-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Recombinant pox virus for immunization against tumor-associated antigens
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
WO1999008713A1 (en) * 1997-08-13 1999-02-25 The Uab Research Foundation Vaccination by topical application of genetic vectors
ES2286530T3 (es) * 1997-10-10 2007-12-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Peptidos antagonistas del antigeno carcinoembrionario (cea).
US6756038B1 (en) 1997-10-10 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
EP1447414B1 (en) * 1997-10-10 2007-06-06 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Antagonist peptides of carcinoembryonic antigen (CEA)
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7060670B1 (en) * 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
ES2447115T3 (es) * 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
DE60038971D1 (de) 1999-10-22 2008-07-03 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
AU5810201A (en) 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
EP1305414A2 (en) * 2000-07-31 2003-05-02 Aventis Pasteur Limited Modified cea and uses thereof
EP1313505A4 (en) * 2000-09-01 2005-10-12 Epimmune Inc HLA BINDING PEPTIDES AND THEIR USES (18.03.02)
DE60209345T2 (de) * 2001-03-08 2006-08-03 Akzo Nobel N.V. Leporipox-basierende vektorvakzine
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
AU2002347317B2 (en) 2001-11-30 2008-06-26 Isis Innovation Limited Vaccine
WO2003082317A1 (en) * 2002-03-22 2003-10-09 Zycos, Inc. Peptide epitopes recognized by antigen specific cd8+ t lymphocytes
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
RU2334235C2 (ru) * 2002-06-11 2008-09-20 Мерк Патент Гмбх Способ картирования и устранения эпитопов т-клеток
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
WO2005058937A2 (en) * 2003-12-12 2005-06-30 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
EP2023954B1 (en) * 2006-05-19 2013-07-17 Sanofi Pasteur, Inc. Immunological composition
EP2918598B1 (en) * 2007-02-28 2019-01-30 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
US9670506B2 (en) 2009-04-30 2017-06-06 Consejo Superior De Investigaciones Cientificas Modified immunization vectors
US9804163B2 (en) 2010-08-06 2017-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for prostate cancer and methods for their detection
EP2895191B1 (en) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
JP2018526034A (ja) 2015-09-10 2018-09-13 アフィジェン・インコーポレイテッド 腫瘍治療薬の配列決定により導かれる選択
EP3400009A2 (en) 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
SG10201914014XA (en) 2016-06-03 2020-03-30 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
ES2059330T3 (es) * 1986-08-13 1994-11-16 Miles Inc Un cdna codificador de antigeno carcinoembrionico.
JPH02107189A (ja) * 1988-05-25 1990-04-19 City Of Hope 癌胎児抗原フラグメント
JP3399943B2 (ja) * 1991-05-06 2003-04-28 アメリカ合衆国 癌胎児性抗原を発現する組換えウイルスとその使用方法
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5764734A (en) * 1994-12-21 1998-06-09 Motorola, Inc. Method and system for controlling access to a channel

Also Published As

Publication number Publication date
PT811062E (pt) 2009-09-28
AU5024096A (en) 1996-09-11
JP4059920B2 (ja) 2008-03-12
CA2213451C (en) 2013-11-12
WO1996026271A1 (en) 1996-08-29
ES2329427T3 (es) 2009-11-25
AU711899B2 (en) 1999-10-21
EP0811062B1 (en) 2009-07-15
EP0811062A1 (en) 1997-12-10
US6319496B1 (en) 2001-11-20
DE69637969D1 (de) 2009-08-27
CA2213451A1 (en) 1996-08-29
JPH11507804A (ja) 1999-07-13
US6001349A (en) 1999-12-14

Similar Documents

Publication Publication Date Title
DK0811062T3 (da) Frembringelse af humane cytotoksiske T-celler, der er specifikke for selvassocierede antigener af carcinomer, og anvendelser heraf
NO931138D0 (no) Omco-foetalt gen, genprodukt og anvendelse derav
DK218386D0 (da) Konjugater af antistof og terapeutisk middel
NO165288C (no) Silisiumpulver og fremgangsmaate for fremstilling av silisiumpulver.
DK197889D0 (da) Fremgangsmaade til fremstilling af flokfiber-overfoeringsmateriale, saadant materiale, fremgangsmaade til fremstilling af en folie til saadant materiale og fremgangsmaade til paafoering af saadant materiale
DE69009540D1 (de) Arzneimittel enthaltendes Heftpflaster.
DK335389A (da) Komposit-agrotekstil og anvendelser af dette
NO885628L (no) Fremgangsmaate for fremstilling av bundet partikkelformig materiale og bindemiddel for bruk deri.
IS3721A7 (is) Viðskeytt benzimidazole, aðferð við lögun þeirra og lyfjafræðileg notkun
DK0808249T3 (da) Sammensætninger og donorelementer til termisk masseoverføring til anvendelse ved fremstilling af produkter til skiltning
FI841448A (fi) Anordning foer upprullning av en materialbana, speciellt en pappersbana, pao en hylsa.
NO172806C (no) Vannherdende polymertilberedning, fremstilling og anvendelse derav
DE3882727D1 (de) Mycoplasma-membran-antigene und ihre verwendung.
DK436184D0 (da) Specifikke cea-familie-antigener, antistoffer specifikke dertil og deres anvendelsesmaader
NO962157D0 (no) Nye glukose- og soforoselipider, en fremgangsmåte for fremstilling derav og anvendelse av lipidene
DK643587D0 (da) I det vaesentlige rent praeparat af et enzym/antistof-konjugat, dets fremstilling og anvendelse.
DK307385A (da) Morpholinolforbindelser, deres fremstilling og farmaceutiske anvendelse
EP0306680A3 (en) Monoclonal antibodies to anti-thrombin binding substance, and their uses
NO893818D0 (no) Produksjon og anvendelse av hybride, monoklonale antistoffer.
DK0869952T3 (da) Derivater af 5-naphthalen-1-yl-1,3-dioxaner, fremstilling og terapeutisk anvendelse heraf
BR8900109A (pt) Colar protetor
IT8322223A0 (it) Procedimento per produrre una foglia adatta come materiale elettroisolante e impiego di tale foglia.
NO912509D0 (no) Fremgangsmaate for fremstilling av substituerte acykliske nukleosider og mellomprodukter derav.
NO901302D0 (no) Fremgangsmaate for fremstilling av karbonfattige, finfordelte pulvere av keramisk materiale.
DK141789A (da) Faste, isaer faste orale og rektale, etofenamatholdige laegemidler